APRI - Apricus Biosciences, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
0.2901
+0.0051 (+1.79%)
At close: 3:56PM EST

0.2890 -0.00 (-0.38%)
After hours: 5:14PM EST

Stock chart is not supported by your current browser
Previous Close0.2850
Open0.2950
Bid0.2400 x 1000
Ask0.3080 x 800
Day's Range0.2800 - 0.2950
52 Week Range0.2500 - 3.3400
Volume154,848
Avg. Volume768,339
Market Cap8.171M
Beta (3Y Monthly)1.12
PE Ratio (TTM)N/A
EPS (TTM)-0.5020
Earnings DateMay 9, 2018 - May 14, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est1.25
Trade prices are not sourced from all markets
  • GlobeNewswire3 days ago

    Apricus Biosciences Reminds Shareholders to Vote Before the Special Meeting on December 14, 2018

    Apricus Biosciences, Inc. (APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, reminds shareholders to vote by proxy before the upcoming special stockholders meeting on December 14, 2018.  Apricus is holding a special meeting of stockholders in order to obtain the stockholder approvals required pursuant to the terms of the Merger Agreement with Seelos Therapeutics, Inc. and the Securities Purchase Agreement to finance the post-merger corporation or necessary under Nevada law, in order to complete the merger, the financing and related matters. The Apricus special meeting will be held at 8:00 a.m., Pacific time, on December 14, 2018 at Latham & Watkins LLP, located at 12670 High Bluff Drive, San Diego, California 92130, unless postponed or adjourned to a later date.  If you have questions or need help voting your shares, please call our proxy solicitation firm, Morrow Sodali LLC at 1-877-787-9239.

  • GlobeNewswire27 days ago

    Report: Exploring Fundamental Drivers Behind Zedge, Apricus Biosciences, AquaBounty Technologies, Clarus, Dynasil Corporation of America, and The Rubicon Project — New Horizons, Emerging Trends, and Upcoming Developments

    NEW YORK, Nov. 16, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • Associated Presslast month

    Apricus: 3Q Earnings Snapshot

    On a per-share basis, the San Diego-based company said it had a loss of 12 cents. In the final minutes of trading on Wednesday, the company's shares hit 35 cents. A year ago, they were trading at $1.67. ...

  • GlobeNewswirelast month

    Apricus Biosciences Provides Corporate Update and Third Quarter 2018 Financial Results

    Apricus Biosciences, Inc. (APRI), a biopharmaceutical company historically focused on seeking to advance innovative medicines in urology and rheumatology, today reported financial results for the third quarter and year-to-date for 2018 and provided a corporate update on its pending merger with Seelos Therapeutics, Inc. On July 30, 2018, the Company announced the signing of a definitive agreement to merge with Seelos Therapeutics, Inc., a privately-held biotechnology company, in an all-stock transaction. The merged company will focus on the development and commercialization of central nervous system (CNS) therapeutics with known mechanisms of action in areas with a highly unmet medical need.

  • Associated Press4 months ago

    Apricus: 2Q Earnings Snapshot

    On a per-share basis, the San Diego-based company said it had a loss of 10 cents. In the final minutes of trading on Thursday, the company's shares hit 27 cents. A year ago, they were trading at $1.33. ...

  • ACCESSWIRE5 months ago

    Breakfast Technical Briefing on Amarin and Three Other Additional Biotech Stocks

    On Friday, June 29, 2018, US markets saw broad based gains with six out of nine sectors finishing the trading sessions in green. All you have to do is sign up today for this free limited time offer by clicking the link below.

  • What Does Apricus Biosciences Inc’s (NASDAQ:APRI) Share Price Indicate?
    Simply Wall St.6 months ago

    What Does Apricus Biosciences Inc’s (NASDAQ:APRI) Share Price Indicate?

    Apricus Biosciences Inc (NASDAQ:APRI), a pharmaceuticals company based in United States, received a lot of attention from a substantial price movement on the NasdaqCM over the last few months, increasingRead More...

  • ACCESSWIRE6 months ago

    Complimentary Technical Snapshots on Axovant Sciences and Three More Biotech Stocks

    LONDON, UK / ACCESSWIRE / June 4, 2018 / If you want a free Stock Review on AXON sign up now at www.wallstequities.com/registration. In today's pre-market research, WallStEquities.com scans Actinium Pharmaceuticals Inc. (NYSE AMER: ATNM), Amarin Corp. PLC (NASDAQ: AMRN), Apricus Biosciences Inc. (NASDAQ: APRI), and Axovant Sciences Ltd (NASDAQ: AXON).

  • With A -24.18% Earnings Drop, Is Apricus Biosciences Inc’s (NASDAQ:APRI) A Concern?
    Simply Wall St.7 months ago

    With A -24.18% Earnings Drop, Is Apricus Biosciences Inc’s (NASDAQ:APRI) A Concern?

    After looking at Apricus Biosciences Inc’s (NASDAQ:APRI) latest earnings update (31 March 2018), I found it helpful to revisit the company’s performance in the past couple of years and compareRead More...

  • Associated Press7 months ago

    Apricus: 1Q Earnings Snapshot

    On a per-share basis, the San Diego-based company said it had a loss of 14 cents. In the final minutes of trading on Thursday, the company's shares hit 26 cents. A year ago, they were trading at $1.16. ...

  • GlobeNewswire7 months ago

    Apricus Biosciences Provides Corporate Update and First Quarter 2018 Financial Results:

    Company Pursuing U.S. Vitaros Partnership and Strategic Alternatives SAN DIEGO, May 03, 2018 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company seeking to advance ...

  • Benzinga8 months ago

    Benzinga Pro's 5 Stocks To Watch Today

    Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! Netflix, Inc. (NASDAQ: NFLX ) stock was trading higher ...

  • Reuters8 months ago

    Apricus mulls options; to sell U.S. rights to Vitaros

    Apricus Biosciences Inc said on Monday it was considering options for the company and looking to sell the U.S. rights to its erectile dysfunction cream Vitaros, after the Food and Drug Administration asked it to make a new formula for the product. Shares of the company fell 24 percent to 32 cents in premarket trading, valuing the company at $7.5 million.

  • Reuters8 months ago

    FDA asks for new formulation of Apricus' erectile dysfunction cream

    Drugmaker Apricus Biosciences Inc said on Monday the U.S. regulator directed it to develop a new formulation for its erectile dysfunction cream, Vitaros, which was rejected in February. The U.S. Food And ...

  • GlobeNewswire8 months ago

    Apricus Biosciences Announces Outcome of Vitaros(TM) End-of-Review Meeting with FDA

    FDA Confirms Vitaros Regulatory Pathway  Company Seeking Partner to Develop Vitaros in U.S. Company Evaluating Strategic Alternatives SAN DIEGO, April 16, 2018 (GLOBE NEWSWIRE) -- Apricus Biosciences, ...

  • Market Exclusive9 months ago

    Edge Therapeutics And Apricus Biosciences Are Moving: Here’s Why

    Edge Therapeutics, Inc. (NASDAQ:EDGE) is grabbing all of the headlines in the biotechnology space heading into the close of this week on news that a trial rooted in one of its lead development assets has failed to hit the mark. The trial in question was looking at a drug called EG-1962. This is one of […] The post Edge Therapeutics And Apricus Biosciences Are Moving: Here’s Why appeared first on Market Exclusive.

  • GlobeNewswire9 months ago

    Apricus Biosciences Announces Pricing of $3.55 Million Public Offering

    SAN DIEGO, March 28, 2018 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that it has ...

  • GlobeNewswire9 months ago

    Apricus Biosciences Announces Proposed Public Offering

    SAN DIEGO, March 27, 2018 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that it has ...